Providers assess whether GLP-1 aligns with your overall treatment plan, particularly if you take other medications or have conditions affecting medication metabolism
Genetics can influence how you respond to the drug
The ASA admits they are not sure how long patients need to fast from this medicine to prevent aspiration during surgery
These are the newer GLP-1 therapies that have shown superior results to prior therapies in lowering A1C (blood sugar) levels of diabetics and helping those who are obese lose weight
Dan Kenger, the chief design officer at Hims & Hers, told me in an email that the actors in the commercial represent only symbols of an intimidating, members-only healthcare culture. But the parallels to real life are too obvious to ignore
Key findings: 12 mg dose: Average weight loss of 24.2% of body weight (approximately 58 lbs for a 240 lb individual) 8 mg dose: Average weight loss of 22.8% 4 mg dose: Average weight loss of 17.0% Placebo: Average weight loss of 2.1% Over 90% of participants receiving the 8 mg or 12 mg dose lost at least 10% of body weight Over 75% of participants at the highest dose lost at least 20% of body weight Significant improvements in waist circumference, blood pressure, and lipid profiles were observed across dose groups Phase 2 Trial in Type 2 Diabetes A separate phase 2 trial evaluated retatrutide in adults with type 2 diabetes and obesity (Rosenstock et al., Lancet , 2023)
